Elicera Therapeutics AB banner
E

Elicera Therapeutics AB
STO:ELIC

Watchlist Manager
Elicera Therapeutics AB
STO:ELIC
Watchlist
Price: 5.62 SEK -0.88% Market Closed
Market Cap: kr272.8m

Multiples-Based Value

The Multiples-Based Value of one ELIC stock under the Base Case scenario is hidden SEK. Compared to the current market price of 5.62 SEK, Elicera Therapeutics AB is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ELIC Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

ELIC Competitors Multiples
Elicera Therapeutics AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Elicera Therapeutics AB
STO:ELIC
272.8m SEK 25.1 -15.7 -13.8 -13.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
370.2B USD 6.1 88.4 14.7 20.4
US
Exact Sciences Corp
NASDAQ:EXAS
355.4B USD 109.4 -1 708.3 15 870 -1 791.9
US
Amgen Inc
NASDAQ:AMGN
188B USD 5.1 24.4 14.1 14.1
US
Gilead Sciences Inc
NASDAQ:GILD
166.6B USD 5.7 19.6 12.3 15.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD 9.2 27.8 20.9 21.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD 5.4 17.3 12.7 14.5
AU
CSL Ltd
ASX:CSL
69.6B AUD 3.2 34.9 11.5 14.4
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
SE
E
Elicera Therapeutics AB
STO:ELIC
Average P/S: 3 063 013.9
25.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
9%
0.7
US
Exact Sciences Corp
NASDAQ:EXAS
109.4
12%
9.1
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.7
5%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.2
11%
0.8
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
10%
0.5
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
SE
E
Elicera Therapeutics AB
STO:ELIC
Average P/E: 35.4
Negative Multiple: -15.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.4
97%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -1 708.3 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.4
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
19.6
16%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
13%
1.3
AU
CSL Ltd
ASX:CSL
34.9
10%
3.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
E
Elicera Therapeutics AB
STO:ELIC
Average EV/EBITDA: 2 279.5
Negative Multiple: -13.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.7
12%
1.2
US
Exact Sciences Corp
NASDAQ:EXAS
15 870
261%
60.8
US
Amgen Inc
NASDAQ:AMGN
14.1
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.9
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
18%
0.7
AU
CSL Ltd
ASX:CSL
11.5
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
E
Elicera Therapeutics AB
STO:ELIC
Average EV/EBIT: 16.7
Negative Multiple: -13.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.4
23%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -1 791.9 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.1
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.1
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.8
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.5
23%
0.6
AU
CSL Ltd
ASX:CSL
14.4
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett